Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02791906 · ClinicalTrials.gov registry record · Phase 2

Targeting Central Pulsatile Hemodynamics in Chronic Kidney Disease

A Phase 2 study, sponsored by University of Pennsylvania.

Terminated
Registry status
Phase 2
Development phase
8
Enrollment target

NCT02791906: Clinical Trial Phase 2 study, sponsored by University of Pennsylvania.

NCT02791906 is a Phase 2 study that was terminated before completion, run by University of Pennsylvania. The registered enrollment target is 8 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02791906, a Phase 2 study, was terminated before completion, sponsored by University of Pennsylvania.

TERMINATED
Registry status
Phase 2
Development phase
8 participants
Enrollment target

Study Summary

Heart failure (HF) is an epidemic and is a major burden on the US healthcare system. The most common cardiovascular endpoint is HF. Thus, novel interventions to prevent HF in chronic kidney disease (CKD) are highly desirable. This study will assess: the variability in the response to isosorbide mononitrate (ISMN) therapy; the degree of change in central hemodynamics and cardiac endpoints through analysis of changes in left ventricle (LV) mass, diffuse myocardial fibrosis, and myocardial systolic and diastolic function.

Interventions

  • DIETARY_SUPPLEMENT Vitamin C
  • DRUG ISMN

Trial Details

FieldValue
Enrollment Target 8 participants
Start Date 2016-05
Est. Completion 2019-03
Phase Phase 2

Sponsor

University of Pennsylvania

1,423 total trials

What the Registry Record Tells You About NCT02791906

The ClinicalTrials.gov registry entry for NCT02791906 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Vitamin C is the first listed.

NCT02791906 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02791906 about?

NCT02791906 is a clinical study titled "Targeting Central Pulsatile Hemodynamics in Chronic Kidney Disease". Heart failure (HF) is an epidemic and is a major burden on the US healthcare system. The most common cardiovascular endpoint is HF. Thus, novel interventions to prevent HF in chronic kidney disease (CKD) are highly desirable. This study will assess: the variability in the response to isosorbide mono...

What is the current status of trial NCT02791906?

This trial is currently terminated. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2016-05. Estimated completion is 2019-03.

What interventions are being tested in trial NCT02791906?

The interventions under investigation include: Vitamin C (DIETARY_SUPPLEMENT), ISMN (DRUG).

Who is sponsoring clinical trial NCT02791906?

This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.